Genmab is positioning its next catalyst slate as its Darzalex revenue stream faces major patent-loss exposure. The company’s strategy hinges on late-stage and near-term readouts for multiple oncology programs, including Epkinly in first-line lymphoma and ADC assets such as rinatabart sesutecan (Rina-S), alongside the bispecific petosemtamab acquired in Genmab’s Merus deal. With Darzalex royalties projected to shrink materially after patent expirations, the near-term clinical data calendar is framed as pivotal for whether Genmab can sustain growth beyond the so-called “cliff” period. Analysts highlighted Epkinly and Rina-S as key validation points, while petosemtamab is described as the most important ramp candidate. The update matters for investors and partners evaluating the stability of Genmab’s pipeline economics as a core franchise transitions from protection to renewal.